protalix.com (PLX) Company Annual Revenue

Current sales of Protalix BioTherapeutics (PLX) on GURU.Markets are reflected in this chart through the lens of in-house protein production, which minimizes reliance on third-party plants. Revenues are based on Gaucher disease therapy for insurance funds, while exclusive distribution agreements ensure the stability of the ecosystem. The value is maintained at 0.08, allowing for a comparison of current revenue with the asset's historical performance.

This indicator aggregates daily revenue, allowing for the verification of actual cash flow through the lens of financial reporting. This metric captures real customer receipts, eliminating market noise. For Protalix BioTherapeutics (PLX), this is a critical marker for the commercialization of the ProCellEx platform under strict FDA oversight. By analyzing the company's current sales volume, investors can assess the effectiveness of overcoming regulatory barriers. The trend line confirms the viability of the business model.